The discovery of immune checkpoints has led to the development of a new type of inhibitor (e.g., antibodies targeting the PD-1/PD-L1 axis and CTLA-4) that prevents the tumor from blocking the immune response4–6. This evidence concerns the gene CD274 and neoplasm.